Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001140361-25-007015·Indivior Pharmaceuticals, Inc.
Schedule 13D ownership disclosure
INDIVIOR PLC
Ordinary Shares, $0.50 nominal value per share · CUSIP: G4766E116
Event date: 2025-02-28
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Oaktree Value Opportunities Fund, L.P.
Shares: 6,237,438 · Class: 5%
- Oaktree London Liquid Value Opportunities Fund (VOF), L.P.
Shares: 2,594,929 · Class: 2.1%
- Oaktree Phoenix Investment Fund, L.P.
Shares: 367,390 · Class: 0.3%
- Oaktree Capital Management, L.P.
Shares: 1,516,134 · Class: 1.2%
- Oaktree Fund GP I, L.P.
Shares: 9,199,757 · Class: 7.4%
- Oaktree Capital Holdings, LLCReported CIK 0001790787
Shares: 10,715,891 · Class: 8.6%
- Oaktree Capital Group Holdings GP, LLC
Shares: 10,715,891 · Class: 8.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001140361-25-007015
- Form type
- SCHEDULE 13D/A
- Filer
- Indivior Pharmaceuticals, Inc.
- CIK
- CIK 1625297
- Filed
- Mar 04, 2025
- Reporting period
- Feb 28, 2025
- Description
- Schedule 13D beneficial ownership